Premium
Influence of acute viral hepatitis on phenytoin kinetics and protein binding
Author(s) -
Blaschke Terrence F.,
Meffin Peter J.,
Melmon Kenneth L.,
Rowland Malcolm
Publication year - 1975
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1975176685
Subject(s) - albumin , phenytoin , medicine , viral hepatitis , pharmacokinetics , hepatitis , liver disease , bilirubin , serum albumin , liver function tests , liver function , pharmacology , acute hepatitis , gastroenterology , blood proteins , immunology , psychiatry , epilepsy
Patients with liver disease are thought to have abnormal responses to drugs metabolized by the liver. although supportive evidence is sparse. The influence of acute viral hepatitis on the pharmacokinetics and protein binding of phenytoin (DPH) was examined in 5 patients. A longitudinal study design was used so that each patient acted as his own control. DPH clearance was unaffected by acute viral hepatitis over the concentration range studied. but the percentage of un bound DPH increased by an average of nearly one‐third during acute viral hepatitis. A small decline in serum albumin concentration and elevated serum bilirubin levels may be responsible for the alterations in protein binding. These results indicate that acute inflammatory liver disease has complex and perhaps paradoxical effects on drug disposition. Clinical and laboratory observations including plasma drug concentrations. still provide the best means for adjusting dosage regimens in patients with fluctuating hepatic function.